InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.680
+0.010 (0.60%)
Apr 29, 2026, 12:34 PM EDT - Market open
InflaRx Revenue
In the year 2025, InflaRx had annual revenue of 29.33K EUR, down -82.31%. InflaRx had revenue of -33.93K in the quarter ending December 31, 2025, with 7,921.51% growth.
Revenue (ttm)
29.33K EUR
Revenue Growth
-82.31%
P/S Ratio
3,505.69
Revenue / Employee
451 EUR
Employees
65
Market Cap
121.45M USD
Revenue Chart
* This company reports financials in EUR.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Verrica Pharmaceuticals | 35.58M |
| Innate Pharma | 10.57M |
| Equillium | 4.39M |
| Cardiff Oncology | 593.00K |
| Genelux | 8.00K |
IFRX News
- 1 day ago - InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 20 days ago - InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 4 weeks ago - InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 6 weeks ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - InflaRx to Report Full Year 2025 Results on March 19, 2026 - GlobeNewsWire